Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | ASPH | Q12797 | 5/20 | 0.50 |
| ▸ | KDM8 | Q8N371 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30049082 | 1.00 | KDM4E (0.50) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL28582520 | 0.98 | KDM4E (0.48) | KDM4EASPHKDM8ALDH1A1MAPT | |
| Cyclopropane SCHEMBL11660772 | 0.94 | KDM4E (0.46) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL6578250 | 0.88 | KDM4E (0.43) | KDM4EASPHKDM8ALDH1A1MAPT | |
| Crotonaldehyde SCHEMBL10573229 | 0.85 | KDM4E (0.39) | KDM4EASPHKDM8ALDH1A1MAPT | |
| Crotonaldehyde SCHEMBL10573246 | 0.85 | KDM4E (0.39) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL9837598 | 0.83 | KDM4E (0.45) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL28380748 | 0.82 | KDM4E (0.63) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL353204 | 0.81 | KDM4E (0.40) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL7199668 | 0.81 | KDM4E (0.47) | KDM4EASPHKDM8ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590343-B2 | Corrosion inhibitor composition for magnesium or magnesium alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2020-03-17 | — | — | US | claimed |
| CN-109467531-A | A kind of preparation method of substituted pyridines dicarboxylic acid derivatives | 沈阳科创化学品有限公司 | 2019-03-15 | — | — | CN | claimed |
| EP-3284847-B1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | HELMHOLTZ ZENTRUM GEESTHACHT (DE) | 2019-01-02 | — | — | EP | claimed |
| EP-3284847-A1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH (DE) | 2018-02-21 | — | — | EP | claimed |
| US-20180044590-A1 | Corrosion Inhibitor Composition for Magnesium or Magnesium Alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2018-02-15 | — | — | US | claimed |
| CN-1067379-C | Process of 5-(substituted methyl)-2,3-pyridinedicarboxylic acids | AMERICAN CYANAMID CO (US) | 2001-06-20 | — | — | CN | claimed |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| EP-4405352-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-117980303-A | Novel compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023041756-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-23 | — | — | WO | disclosed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| US-5122608-A | Hydrolysis ofa 2,3-pyridine- or quinolinedicarboxylic acid diester with water and a acid having an ionization constant of 3; treating with a base and separating | AMERICAN CYANAMID COMPANY (US) | 1992-06-16 | — | — | US | disclosed |
| CN-1061595-A | Be used as new heterocyclics of excited amino acid receptor antagonists and its production and use | AKTIEBOTAGEL ASTRA (SE) | 1992-06-03 | — | — | CN | disclosed |
| EP-0259687-B1 | METHOD FOR THE PREPARATION OF PYRIDINE-2,3-DICARBOXYLIC ACIDS | AMERICAN CYANAMID COMPANY (US) | 1991-07-03 | — | — | EP | disclosed |
| US-4816588-A | OXIDATION OF 8-SUBSTITUTED QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1989-03-28 | — | — | US | disclosed |
| EP-0259687-A2 | Method for the preparation of pyridine-2,3-dicarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1988-03-16 | — | — | EP | disclosed |
| US-4259527-A | OXIDATION OF SECONDARY ALCOHOLS TO KETONES WITH HYDROGEN PEROXIDE | ALLIED CHEMICAL CORPORATION (US) | 1981-03-31 | — | — | US | disclosed |
| US-4171313-A | OF ALICYCLIC KETONES TO LACTONES, W-HYDROXY ACIDS AND ESTERS USING HYDROGEN PEROXIDE AS AN OXIDIZING AGENT | ALLIED CHEMICAL CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | C3AR1, LTB4R, C5 | KDM4E 4227/4885ASPH 2297/4885KDM8 4643/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | KDM4E 4195/4885ASPH 2262/4885KDM8 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.